<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01450605</url>
  </required_header>
  <id_info>
    <org_study_id>AI424-414</org_study_id>
    <nct_id>NCT01450605</nct_id>
  </id_info>
  <brief_title>Korean Post-marketing Surveillance for Reyataz®</brief_title>
  <official_title>Korean Post-marketing Surveillance for Reyataz®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this post-marketing surveillance is to investigate and confirm the type and
      incidence of newly identified adverse events and any other factors affecting safety and
      efficacy of Reyataz® so that the regulatory authority can manage the marketing approval
      properly
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events occurrence</measure>
    <time_frame>30 days after last dose of study drug</time_frame>
    <description>Incidence (per person-time) and confidence interval of overall adverse events and each adverse event will be computed per surveillance period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Human Immunodeficiency Virus (HIV) Ribonucleic acid (RNA) level before and after drug administration</measure>
    <time_frame>Baseline and 16 weeks after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD 4 T-cell count before and after drug administration</measure>
    <time_frame>Baseline and 16 weeks after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall efficacy evaluation by investigator's discretion</measure>
    <time_frame>Baseline and 16 weeks after first treatment</time_frame>
    <description>Based on laboratory test results including HIV RNA (viral load) and CD4 T-cell count, clinical findings, subjective findings and objective findings in comparison to baseline</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">601</enrollment>
  <condition>HIV-1</condition>
  <arm_group>
    <arm_group_label>Patients ≥ 13 years of age with HIV-1</arm_group_label>
    <description>Patients ≥ 13 years of age with HIV-1 who are on Reyataz® treatment at the time of enrollment and have never been participated in this study previously or who are initiating Reyataz® treatment for the first time in the real-life conditions in its registered indication(s) as required by KFDA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No Intervention</intervention_name>
    <description>Patients are previously on Reyataz® treatment or initiated Reyataz® for the first time</description>
    <arm_group_label>Patients ≥ 13 years of age with HIV-1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients ≥ 13 years of age with HIV-1 who are on Reyataz® treatment at the time of
        enrollment and have never been participated in this study previously or who are initiating
        Reyataz® treatment for the first time in the real-life conditions in its registered
        indication(s) as required by KFDA
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥ 13 years of age with HIV-1 who are on Reyataz® treatment at the time of
             enrollment and have never been participated in this study previously or who are
             initiating Reyataz® treatment for the first time in the real-life conditions in its
             registered indication(s) as required by KFDA

        Exclusion Criteria:

          -  According to Warning/Caution in local label
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>110-756</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2011</study_first_submitted>
  <study_first_submitted_qc>October 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2011</study_first_posted>
  <last_update_submitted>April 20, 2016</last_update_submitted>
  <last_update_submitted_qc>April 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atazanavir Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

